MedPath

PENS or TENS for Pain in Liver Cancer

Not Applicable
Completed
Conditions
Cancer Pain
Pain
Liver Neoplasms
Interventions
Device: PENS
Device: TENS
Registration Number
NCT03338543
Lead Sponsor
Fuda Cancer Hospital, Guangzhou
Brief Summary

This study evaluates the effect of percutaneous electrical nerve stimulation (PENS) and transcutaneous nerve stimulation (TENS) for pain relieving in patients with liver cancer. Patients will randomly allocated into PENS group, Tens group and control group.

Detailed Description

PENS and TENS have been reported with analgesic effect in patients with pain, including cancer pain, lower back pain, neck pain, stomachache and so on. Effect and mechanism of PENS on pain relieving has been widely researched. With additional electrical stimulation in certain frequency and intensity to conventional acupuncture, pain controlling effect has been largely enhanced. However, invasive operation limits its application and acceptability, especially on pancreatic cancer. TENS is an advanced technique generated from PENS, which is much more welcome for its noninvasive character. Further more, its analgesic effect on cancer pain has been proved by several multi-central, randomized, clinical trials.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria
  • Primary liver cancer with pain;
  • Haven't underwent neurolytic celiac plexus block in the past 1 month;
  • With anticipatory survival of more than 3 months.
Exclusion Criteria
  • Metastatic liver cancer;
  • Can not tolerate a flat or side lying or sitting prostrate for 30 min;
  • performance score>3;
  • Who has been recruited in other clinical trial for pain relieving;
  • Who underwent radiotherapy or local radioactive seeds implantation for pain relieving in the past month;
  • Imaging diagnosed with encephalic tumor or metastasis;
  • Who with cardiac pacemaker or metal stand;

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
percutaneous stimulationPENSPENS in 2/100 hertz (HZ), 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
transcutaneous stimulationTENSTENS in 2/100 HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
Primary Outcome Measures
NameTimeMethod
pain scoreday0 to day6

pain score assessed via visual analogue scale (VAS)

Secondary Outcome Measures
NameTimeMethod
quantity of analgesic medicationday0 to Day6

decreasing in quantity of analgesic medication

times of breakthrough pain (BTP)day0 to day6

times of BTP per day

Trial Locations

Locations (1)

Fuda Cancer Hospital

🇨🇳

Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath